DPP4 antagonists, metformin, and SGLT2 inhibitors, and thiazolidinediones have been demonstrated to have favorable effects on NAFLD in T2DM patients [44, 45]. The gene discussed is DPP4; the disease is metabolic dysfunction-associated steatotic liver disease.